-+ 0.00%
-+ 0.00%
-+ 0.00%

Xenetic Biosciences Announces Its Collaboration Partner PeriNess Doses First Participant In Clinical Trial Of Systemic Recombinant Human DNase To Treat Large B-Cell Lymphoma In Israel

Benzinga·10/15/2026 12:49:28
Listen to the news

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma ("LBCL") at the Tel Aviv Sourasky University Medical Center ("Ichilov Center") in Israel.